LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $112.60 Average Target Price from Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have earned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $112.60.

A number of brokerages recently weighed in on LMAT. Barrington Research reaffirmed an “outperform” rating and set a $120.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, June 3rd. Weiss Ratings raised LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 20th. Citizens Jmp upped their price objective on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Roth Mkm reaffirmed a “buy” rating and set a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Finally, Wells Fargo & Company upped their price objective on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th.

LeMaitre Vascular Trading Up 1.6%

NASDAQ:LMAT opened at $93.39 on Friday. The firm has a market cap of $2.13 billion, a P/E ratio of 34.46, a PEG ratio of 2.55 and a beta of 0.54. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. The stock’s 50 day simple moving average is $103.45 and its 200-day simple moving average is $96.22. LeMaitre Vascular has a 12-month low of $79.00 and a 12-month high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. The business had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.48 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities analysts anticipate that LeMaitre Vascular will post 3 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Thursday, May 21st were issued a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend was Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio is currently 36.90%.

Insider Buying and Selling

In related news, CEO George W. Lemaitre sold 27,881 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the transaction, the chief executive officer owned 1,430,019 shares of the company’s stock, valued at $155,428,765.11. This represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Trent G. Kamke sold 2,928 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $107.00, for a total value of $313,296.00. Following the completion of the sale, the insider directly owned 3,749 shares in the company, valued at $401,143. This trade represents a 43.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 54,453 shares of company stock valued at $5,906,174 over the last quarter. Company insiders own 7.40% of the company’s stock.

Institutional Trading of LeMaitre Vascular

Large investors have recently bought and sold shares of the company. Sound Income Strategies LLC grew its holdings in LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 183 shares during the last quarter. Catalyst Capital Advisors LLC acquired a new stake in LeMaitre Vascular in the first quarter valued at $32,000. MAI Capital Management acquired a new stake in LeMaitre Vascular in the third quarter valued at $38,000. Geneos Wealth Management Inc. grew its holdings in LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares during the last quarter. Finally, EverSource Wealth Advisors LLC acquired a new stake in LeMaitre Vascular in the second quarter valued at $47,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.